

China gives emergency nod to Fosun Pharma's COVID-19 test kit

27 March 2020 | News

The kit can complete the detection of 96 samples within two hours



Shanghai Fosun Long March Medical Science Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, has received emergency approval from the National Medical Products Administration (NMPA) for its self-developed novel coronavirus nucleic acid detection kit.

This kit can realize qualitative detection of novel coronavirus ORF1ab, N and E gene targets and can complete the detection of 96 samples within two hours by supporting fast nucleic acid extraction instrument and extraction reagents. In addition, automated testing will lower the risk of operator infection, reduce the risk of cross contamination in the laboratory, and improve detection efficiency.

Meanwhile, with the global outbreak of the pandemic, viral nucleic acid detection kits play a key role in infection prevention. On March 17, Fosun Long March was granted CE certification from the European Union ("EU") for its self-developed novel coronavirus nucleic acid detection kit.